Atrial Fibrillation: A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute

Table 1

Baseline characteristics for novel oral anticoagulant trials.

	RE-LY	ROCKET-AF	ARISTOTLE
Study drug	Dabigatran 150 mg twice daily	Rivaroxaban 20 mg daily	Apixaban 5 mg twice daily
Renal dose adjustment	Dabigatran 110 mg twice daily	Rivaroxaban 15 mg daily	Apixaban 2.5 mg twice daily
Average CHADS2 score	2.2	3.5	2.1
Mean age	71	73	70
Creatinine clearance >30, <50 ml/min	19.4%	20.8%	15.2%
Creatinine clearance >50 ml/min	80.6%	79.2%	83.4%
Prior warfarin use	49.6%	62.4%	57.2%
Prior myocardial infarction	16.6%	17.3%	14.2%
Prior stroke/TIA	20.0%	54.8%	19.4%